Nabriva Analysts Bullish After FDA OKs Antibiotic; BofA Sees $200M Sales Potential
Replimune's Lead Asset Likely Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation
Harpoon Therapeutics' Platform To Drive Significant Value, Wedbush Says In Bullish Initiation
Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation